Oncology Surgery Reproductive medicine (gynecology, andrology, obstetrics)
Author, co-author :
Bolze ✱; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
Schoenen, Sophie ✱; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique
Margaillan; Centre Français de Référence des Maladies Trophoblastiques, CHU Lyon Sud, France.
Braga, A; Rio de Janeiro Trophoblastic Disease Reference Center, Rio de Janeiro, Brazil
Sauthier, Philippe; R ́eseau des Maladies Trophoblastiques Du Qu ́ebec, Montr ́eal, Canada
Elias; New England Trophoblastic Disease Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women’s Hospital, Boston, USA
Seckl, M; Charing Cross Gestational Trophoblastic Disease Center, London, UK
Winter, M; Sheffield Center for Trophoblastic Diseases, Sheffield, UK
Coutler, J; Department of Gynaecology Obstetrics, Cork University Maternity Hospital, Cork, Ireland
Lok, C; Center of Gynaecologic Oncology, Amsterdam, Netherlands
Joneborg, U; Department of Women’s and Children’s Health and Department of Pelvic Cancer, Karolinska Institutet/University Hospital, Stockholm, Sweden
Undurraga Malinverno, M; Unite D’oncogynecologie, Departement de Gynecologie et Obstetrique, Hopitaux Universitaires de Geneve, Geneve, Switzerland
Hajri, T; Centre Français de Reference des Maladies Trophoblastiques, CHU Lyon Sud, France
Massardier, J; Centre Français de R ́ef ́erence des Maladies Trophoblastiques, CHU Lyon Sud, France
You, B; Centre Français de R ́ef ́erence des Maladies Trophoblastiques, CHU Lyon Sud, France
Golfier, F; Centre Français de R ́ef ́erence des Maladies Trophoblastiques, CHU Lyon Sud, France
Goffin, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique (CHR) ; Centre Hospitalier Universitaire de Liège - CHU > > Service de gynécologie-obstétrique
Lurain, J.R., Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Am J Obstet Gynecol 203:6 (2010 Dec), 531–539.
Hui, P., Baergen, R., Cheung, A., Fukunaga, M., Gersell, D., Lage, J.M., et al. Gestational trophoblastic neoplasms. Kurman, R.J., L, C.M., S, H.G., H, Y.R., (eds.) WHO classification of tumours of female reproductive organs, 2014, 158–167 Lyon.
Ngan, H.Y., Bender, H., Benedet, J.L., Jones, H., Montruccoli, G.C., et al. FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 83:Suppl 1 (2003 Oct), 175–177.
Ngan, H.Y.S., Seckl, M.J., Berkowitz, R.S., Xiang, Y., Golfier, F., et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet 155:Suppl 1 (2021 Oct), 86–93 Suppl 1.
Bolze, P.A., Riedl, C., Massardier, J., Lotz, J.P., You, B., et al. Mortality rate of gestational trophoblastic neoplasia with a FIGO score of ≥13. Am J Obstet Gynecol 214:3 (2016 Mar), 390.e1–390.e8.
Freitas, F., Braga, A., Viggiano, M., Velarde, L.G.C., Maesta, I., et al. Gestational trophoblastic neoplasia lethality among Brazilian women: a retrospective national cohort study. Gynecol Oncol 158:2 (2020 Aug), 452–459.
You, B., Pollet-Villard, M., Fronton, L., Labrousse, C., Schott, A.M., et al. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol 21:8 (2010 Aug), 1643–1650.
Strohl, A.E., Lurain, J.R., Postmolar choriocarcinoma: an independent risk factor for chemotherapy resistance in low-risk gestational trophoblastic neoplasia. Gynecol Oncol 141:2 (2016 May), 276–280.
Frijstein, M.M., Lok, C., van Trommel, N.E., Ten Kate-Booij, M.J., Massuger, L., et al. Lung metastases in low-risk gestational trophoblastic neoplasia: a retrospective cohort study. BJOG 127:3 (2020 Feb), 389–395.
Braga, A., Paiva, G., Ghorani, E., Freitas, F., Velarde, L.G.C., et al. Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: a multicentre, retrospective, cohort study. Lancet Oncol 22:8 (2021 Aug), 1188–1198.
Available: https://isstd.org/.
Lok, C., van Trommel, N., Massuger, L., Golfier, F., Seckl, M., Clinical Working Party of the EOTTD. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer 130 (2020 May), 228–240.
Brewer, J.I., Eckman, T.R., Dolkart, R.E., Torok, E.E., Webster, A., Gestational trophoblastic disease. A comparative study of the results of therapy in patients with invasive mole and with choriocarcinoma. Am J Obstet Gynecol 109:2 (1971 Jan 15), 335–340.
Braga, A., Campos, V., Filho, J.R., Lin, L.H., Sun, S.Y., et al. Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?. Gynecol Oncol 148:2 (2018 Feb), 239–246.
Bolze, P.A., Mathe, M., Hajri, T., You, B., Dabi, Y., et al. First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive. Gynecol Oncol 150:2 (2018 Aug), 282–287.
Balachandran, K., Salawu, A., Ghorani, E., et al. When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): a national analysis on over 4,000 patients. Gynecol Oncol 155 (2019), 8–12.
Powles, T., Savage, P.M., Stebbing, J., et al. A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasia. Br J Cancer 96 (2007), 732–737.
Sun, Y., Xiang, Y., Wan, X.R., Yang, X.Y., Factors related to recurrence of choriocarcinoma and evaluation of treatment outcomes. Zhonghua Fu Chan Ke Za Zhi 41:5 (2006 May), 329–332.
Savage, P., Winter, M., Parker, V., Harding, V., Sita-Lumsden, A., et al. Demographics, natural history and treatment outcomes of non-molar gestational choriocarcinoma: a UK population study. BJOG 127:9 (2020 Aug), 1102–1107.
